8e

P.O. Box 50 Experimental Station Road
Newark, DE 19714-0050
Fax (302) 366-5207

8EHQ-1293-1279

DUPONT

DuPont Central Research and Development

A

December 21, 1993

RECD OFFICE OF POLLUTION PREVENTION AND TOXICS
93 DEC 22 PM 2:34

EXPRESS MAIL - RETURN RECEIPT REQUESTED

CONTAINS NO CONFIDENTIAL BUSINESS INFORMATION

Contains No CBI

Document Processing Center (TS-790)
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U. S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460

Dear Coordinator:

This letter is to inform you of the preliminary results of recently conducted acute oral lethality and 2-week inhalation toxicity studies in rats with propanoyl fluoride, 2,3,3,3-tetrafluoro-2-[1,1,2,3,3,3-hexafluoro-2-(heptafluoropropoxy)propoxy]- (CAS No. 2641-34-1).

In the oral study, deaths occurred in male Crl:CD\ rats at dosages of 60 mg/kg of the test substance or greater. Although no deaths occurred at lower dosages (26 or 40 mg/kg), major (approximately 20-30%) weight losses had occurred by study termination.

In the two-week inhalation subchronic study, rats were exposed nose-only to the test substance at concentrations of approximately 5, 50 and 500 ppb for six hours/day, five days/week for two weeks. Although no significant body weight losses were noted in these groups upon animal sacrifice, relative liver weights were 38% and 117% greater than control values in the 50 and 500 ppb groups, respectively. Biochemical analysis of hepatic tissue showed 2- and 5-fold increases in hepatic beta oxidation activity from these groups. Histopathologic evaluation of the liver revealed changes characterized by swollen, eosinophilic hepatocytes which had a granular cytoplasm. Beta oxidation activity and liver morphology in the 5 ppb group were not significantly different from controls.

Based on EPA guidance (1991) for reporting under TSCA Section 8(e), these results appear to be reportable.

Sincerely,

Charles F. Reinhardt

Charles F. Reinhardt, M.D.
Director

CFR/RV:dj
Phone: (302) 366-5285



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Dr. Charles F. Reinhardt
E. I. Du Pont De Nemours and Company
Haskell Laboratory for Toxicology and Industrial Medicine
P.O. Box 50, Elkton Road
Newark, Delaware 19714-0050

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

NOV 0 4 1994

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and **refer to the reverse side of this page for "EPA Information Requests"** .

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan

Terry R. O'Bryan
Risk Analysis Branch

Enclosure 12798 A

Triage of 8(e) Submissions

Date sent to triage: NOV 17 1994

NON-CAP CAP

Submission number: 12798A

TSCA Inventory: Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX EPI RTOX GTOX

STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only

entire document: 0 1 2 **pages** _____ **pages** _____

Notes:

Contractor reviewer : POR **Date:** 9/23/94

CPCATS/TRIAGE TRACKING DBASE ENTRY FORM

CPCATS DATA Submission # 8EHQ 1293-12798 SEQ A

TYPE (INT) SUPP FLWP

SUBMITTER NAME: Dupont Central Research and Development

SUB. DATE: 12/21/93 OTS DATE: 12/23/93 CSB DATE: 01/11/94

INFORMATION REQUESTED: FLWP DATE:
0501 NO INFO REQUESTED
0502 INFO REQUESTED (TECH)
0503 INFO REQUESTED (VOL ACTIONS)
0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:
(0639) REFER TO CHEMICAL SCREENING
0678 CAP NOTICE

VOLUNTARY ACTIONS:
(0401) NO ACTION REPORTED
0402 STUDIES PLANNED/UNDERWAY
0403 NOTIFICATION OF WORKER/OTHERS
0404 LABEL/MSDS CHANGES
0405 PROCESS/HANDLING CHANGES
0406 APP./USE DISCONTINUED
0407 PRODUCTION DISCONTINUED
0408 CONFIDENTIAL

CHEMICAL NAME:	CAS#
	2641-34-1

INFORMATION TYPE:		P F C
0201	ONCO (HUMAN)	01 02 04
0202	ONCO (ANIMAL)	01 02 04
0203	CELL TRANS (IN VITRO)	01 02 04
0204	MUTA (IN VITRO)	01 02 04
0205	MUTA (IN VIVO)	01 02 04
0206	REPRO/TERATO (HUMAN)	01 02 04
0207	REPRO/TERATO (ANIMAL)	01 02 04
0208	NEURO (HUMAN)	01 02 04
0209	NEURO (ANIMAL)	01 02 04
0210	ACUTE TOX. (HUMAN)	01 02 04
0211	CHR. TOX. (HUMAN)	01 02 04
(0212)	ACUTE TOX. (ANIMAL)	(01) 02 04
(0213)	SUB ACUTE TOX (ANIMAL)	(01) 02 04
0214	SUB CHRONIC TOX (ANIMAL)	01 02 04
0215	CHRONIC TOX (ANIMAL)	01 02 04

INFORMATION TYPE:		P F C
0216	EPI/CLIN	01 02 04
0217	HUMAN EXPOS (PROD CONTAM)	01 02 04
0218	HUMAN EXPOS (ACCIDENTAL)	01 02 04
0219	HUMAN EXPOS (MONITORING)	01 02 04
0220	ECO/AQUA TOX	01 02 04
0221	ENV. OCCC/REL/FATE	01 02 04
0222	EMER INCI OF ENV CONTAM	01 02 04
0223	RESPONSE REQEST DELAY	01 02 04
0224	PROD/COMP/CHEM ID	01 02 04
0225	REPORTING RATIONALE	01 02 04
0226	CONFIDENTIAL	01 02 04
0227	ALLERG (HUMAN)	01 02 04
0228	ALLERG (ANIMAL)	01 02 04
0239	METAB/PHARMACO (ANIMAL)	01 02 04
0240	METAB/PHARMACO (HUMAN)	01 02 04

INFORMATION TYPE:		P F C
0241	IMMUNO (ANIMAL)	01 02 04
0242	IMMUNO (HUMAN)	01 02 04
0243	CHEM/PHYS PROP	01 02 04
0244	CLASTO (IN VITRO)	01 02 04
0245	CLASTO (ANIMAL)	01 02 04
0246	CLASTO (HUMAN)	01 02 04
0247	DNA DAM/REPAIR	01 02 04
0248	PROD/USE/PROC	01 02 04
0251	MSDS	01 02 04
0299	OTHER	01 02 04

TRIAGE DATA:	NON-CBI INVENTORY	ONGOING REVIEW	SPECIES	TOXICOLOGICAL CONCERN:	USE:	PRODUCTION
	(YES (CONTINUE))	YES (DROP/REFER)	RAT	(LOW)		
	NO (DROP)	NO (CONTINUE)		(MED)		
	DETERMINE	REFER		HIGH		

COMMENTS Non-Cap

> <ID NUMBER>
8(e)-12798A

> <TOX CONCERN>
L(SBTOX)/M(ATOX)

> <COMMENT>
ACUTE ORAL TOXICITY IN THE RAT IS OF MEDIUM CONCERN. ONLY A SUMMARY IS GIVEN. DEATHS OCCURRED AT DOSAGES OF 60 MG/KG OF THE TEST SUBSTANCE OR GREATER. ALTHOUGH NO DEATHS OCCURRED AT LOWER DOSAGES
(26 OR 40 MG/KG), MAJOR (APPROXIMATELY 20-30%) WEIGHT LOSSES HAD OCCURRED BY STUDY TERMINATION. SUBACUTE INHALATION TOXICITY IN THE RAT IS OF LOW CONCERN. ANIMALS WERE EXPOSED, NOSE ONLY, TO
CONCENTRATIONS OF 5, 50 AND 500 PPM FOR 6 HRS/DAY, 5 DAYS/WEEK FOR TWO WEEKS. THE FOLLOWING OBSERVATIONS WERE MADE IN THE 50 AND 500 PPM GROUPS: BIOCHEMICAL ANALYSIS OF HEPATIC TISSUE SHOWED 2- AND
5-FOLD INCREASES IN HEPATIC BETA OXIDATION ACTIVITY FROM THESE GROUPS. HISTOPATHOLOGIC EVALUATION OF THE LIVER REVEALED CHANGES CHARACTERIZED BY SWOLLEN, EOSINOPHILIC HEPATOCYTES WHICH HAD A GRANULAR
CYTOPLASM.